Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19067809 | Nectin-4 binding miniproteins, conjugates and methods of use thereof | February 2025 | July 2025 | Allow | 4 | 1 | 0 | No | No |
| 19019930 | GAMMA DELTA T CELLS DERIVED FROM INDUCED PLURIPOTENT STEM CELLS, AND PRODUCTION METHOD THEREFOR | January 2025 | August 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18901784 | DENDRITIC CELL PREPARATION AND PREPARATION METHOD THEREOF | September 2024 | July 2025 | Allow | 9 | 2 | 0 | No | No |
| 18203132 | LIPIDOMICS-BASED IDENTIFICATION OF PANCREATIC CANCER PATIENTS | May 2023 | February 2026 | Allow | 33 | 0 | 0 | No | No |
| 18319901 | METHOD FOR CULTURING TUMOR INFILTRATING LYMPHOCYTES | May 2023 | June 2024 | Allow | 13 | 2 | 1 | Yes | No |
| 18314205 | IgG Fc-IL2-Ralpha-IL2 fusions and methods of use thereof | May 2023 | January 2024 | Allow | 9 | 2 | 1 | Yes | No |
| 18314576 | DEVICES AND METHODS FOR ISOLATING TUMOR INFILTRATING LYMPHOCYTES AND USES THEREOF | May 2023 | January 2025 | Abandon | 20 | 2 | 0 | No | No |
| 18298542 | NOVEL IL2 AGONISTS AND METHODS OF USE THEREOF | April 2023 | January 2025 | Abandon | 21 | 1 | 1 | No | No |
| 18188991 | ANTIBODY-DRUG CONJUGATES THROUGH SPECIFIC LINKER OLIGOPEPTIDES | March 2023 | January 2024 | Allow | 10 | 1 | 1 | No | No |
| 18186901 | MODIFICATION OF CAR-T CELLS | March 2023 | February 2024 | Allow | 11 | 2 | 1 | No | No |
| 18176934 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING AN IMMUNE CHECKPOINT INHIBITOR ANTIBODY AND A FUSION PROTEIN COMPRISING AN IL-2 MUTANT AND A CD80 EXTRACELLULAR DOMAIN | March 2023 | March 2026 | Allow | 37 | 1 | 0 | No | No |
| 18089754 | Masked IL-2-Fc fusion polypeptides | December 2022 | October 2023 | Allow | 10 | 1 | 0 | No | No |
| 18088400 | METHODS OF TREATING CASTRATION-RESISTANT PROSTATE CANCER WITH GLUCOCORTICOID RECEPTOR ANTAGONISTS, ANDROGEN DEPRIVATION THERAPY AND ANTI-ANDROGEN RECEPTOR THERAPY | December 2022 | February 2026 | Allow | 38 | 3 | 0 | No | No |
| 18069511 | Anti-CSF1R Antibody and Anti-PD-1 Antibody Combination Therapy for Cancer | December 2022 | December 2025 | Abandon | 36 | 1 | 0 | No | No |
| 18068694 | METHODS OF TREATING BLEEDING DISORDERS BY ADMINISTRATION OF CHIMERAS COMPRISING ANTI-VON WILLEBRAND FACTOR ANTIBODIES AND CLOTTING FACTORS | December 2022 | October 2025 | Allow | 34 | 1 | 0 | No | No |
| 18064793 | TREATMENT OF CANCER WITH IMMUNE STIMULATORS | December 2022 | October 2025 | Allow | 35 | 1 | 1 | No | No |
| 18008877 | LIPID NANOPARTICLES COMPRISING STEROLS AND mRNA | December 2022 | March 2026 | Allow | 39 | 1 | 0 | No | No |
| 18062146 | INTRATUMORAL VACCINATION | December 2022 | December 2025 | Abandon | 36 | 1 | 0 | No | No |
| 18000153 | METHOD OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROME | November 2022 | January 2026 | Allow | 38 | 1 | 0 | No | No |
| 18057591 | AGNOSTIC ANTI-MULLERIAN HORMONE RECEPTOR BINDING PEPTIDES | November 2022 | February 2026 | Allow | 39 | 1 | 1 | No | No |
| 18057465 | POLYNUCLEOTIDES ENCODING ANTI-PD-L1 ANTIBODIES | November 2022 | January 2026 | Allow | 38 | 1 | 0 | No | No |
| 17922882 | METHOD OF TREATMENT OF SOFT TISSUE SARCOMA WITH A PEPTIDE COMRPISING A PCNA INTERACTING MOTIF | November 2022 | November 2025 | Allow | 36 | 1 | 0 | No | No |
| 18050485 | METHOD OF KILLING LEUKEMIA CELLS BY ADMINISTRATION OF RECOMBINANT Y3 PROTEINS | October 2022 | December 2025 | Allow | 37 | 2 | 0 | No | No |
| 17921577 | MITOCHONDRIAL-DERIVED PEPTIDES AND ANALOGS THEREOF FOR USE AS A THERAPY FOR AGE-RELATED DISEASES INCLUDING CANCER | October 2022 | January 2026 | Allow | 39 | 1 | 1 | No | No |
| 17920174 | Manufacturing Process for Heterodimeric IL-12 p35-Fc and p40-FC-Fusion Proteins | October 2022 | July 2025 | Allow | 33 | 0 | 0 | No | No |
| 17968611 | TARGETED HETERODIMERIC FC FUSION PROTEINS CONTAINING NKG2D ANTIGEN BINDING DOMAINS | October 2022 | June 2025 | Allow | 32 | 1 | 0 | No | No |
| 17918175 | INTERFERON TAU AS ANTIVIRAL THERAPY | October 2022 | January 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17995780 | INDIVIDUALIZED THERAPEUTIC ANTICANCER VACCINE | October 2022 | March 2026 | Allow | 41 | 1 | 1 | No | No |
| 17962413 | CD80 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF | October 2022 | October 2025 | Allow | 36 | 1 | 0 | No | No |
| 17938447 | DELIVERY SYSTEM FOR TARGETED DELIVERY OF A THERAPEUTICALLY ACTIVE PAYLOAD | October 2022 | October 2025 | Abandon | 36 | 1 | 1 | No | No |
| 17938109 | PD-1 AND PD-L1 BINDING AGENTS | October 2022 | March 2025 | Allow | 29 | 1 | 1 | No | No |
| 17938092 | Conjugated Fibronectin-Binding Peptides for Use in Tumor or Fibrosis Diagnosis and Therapy | October 2022 | October 2025 | Allow | 37 | 1 | 0 | No | No |
| 17907013 | COMPOSITIONS COMPRISING NON-IMMUNOGENIC RNA ENCODING IMMUNOGENIC EPITOPES AND INTERFERON ALPHA | September 2022 | March 2026 | Allow | 42 | 1 | 1 | No | No |
| 17934113 | Agents and Methods for the Prevention or Treatment of H. Pylori Infections | September 2022 | August 2025 | Allow | 35 | 1 | 1 | No | No |
| 17911891 | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT COMPRISING FUSION PROTEIN INCLUDING IL-2 PROTEIN AND CD80 PROTEIN AND ANTICANCER DRUG | September 2022 | September 2023 | Allow | 12 | 1 | 0 | Yes | No |
| 17911816 | COMBINATION TREATMENT FOR CANCER | September 2022 | January 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17906199 | NEW THERAPEUTIC USE OF ANAKINRA FOR COVID-19 | September 2022 | January 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17944066 | Method of treatment of colorectal, breast and lung cancer with metal containing immune agonist complexes | September 2022 | September 2025 | Allow | 36 | 1 | 1 | No | No |
| 17910532 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | September 2022 | March 2026 | Allow | 42 | 1 | 1 | Yes | No |
| 17930526 | P53, P63, AND P73 HOMO-TETRAMERIC COMPOSITIONS | September 2022 | June 2024 | Allow | 21 | 2 | 1 | No | No |
| 17930555 | METHODS OF ADMINISTERING ANTI-OX40 ANTIBODIES | September 2022 | December 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17930542 | METHODS OF ADMINISTERING ANTI-OX40 ANTIBODIES | September 2022 | December 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17902240 | NON-ADULT HUMAN DOSING OF ANTI-CD30 ANTIBODY-DRUG CONJUGATES FOR TREATMENT OF HEMATOLOGICAL OR LYMPHOID CANCER | September 2022 | January 2025 | Allow | 29 | 0 | 0 | No | No |
| 17908381 | ANTI-EGFR ANTIBODY-DRUG CONJUGATE WITH A CYCLIC DINUCLEOTIDE DERIVATIVE | August 2022 | February 2026 | Allow | 41 | 1 | 1 | No | No |
| 17823356 | COMPLEXES BETWEEN CD40 AND COMPOUNDS COMPRISING BENZIMIDAZOLE MOIETIES | August 2022 | August 2025 | Allow | 35 | 2 | 1 | No | No |
| 17898317 | METHOD FOR TREATING OR SENSITIZING INTERFERON BETA RESISTANT CANCER COMPRISING CFLIP SIRNA | August 2022 | April 2025 | Allow | 32 | 1 | 0 | No | No |
| 17893698 | OXABICYCLOHEPTANES FOR TREATMENT OF SMALL CELL LUNG CANCER | August 2022 | December 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17821459 | TARGETED DELIVERY OF ANTI-CSF1R ANTIBODIES TO JOINTS WITH TENOSYNOVIAL GIANT CELL TUMORS | August 2022 | April 2023 | Allow | 8 | 1 | 0 | No | No |
| 17820794 | METHOD OF TREATING SOLID CANCERS WITH BISPECIFIC INTERLEUKIN-ANTI-TCRß MOLECULES | August 2022 | January 2024 | Allow | 17 | 3 | 1 | Yes | No |
| 17820217 | EXTENDED LOCAL RELEASE OF anti-CSFR1 ANTIBODIES | August 2022 | April 2025 | Allow | 32 | 1 | 0 | No | No |
| 17819911 | RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY | August 2022 | June 2025 | Abandon | 34 | 1 | 0 | No | No |
| 17878221 | NEUREGULIN FOR THE TREATMENT AND/OR PREVENTION OF TUMORS OF THE NERVOUS SYSTEM | August 2022 | June 2025 | Abandon | 34 | 1 | 0 | No | No |
| 17877198 | METHOD OF STIMULATING NEUTROPHIL SURVIVAL AND REDUCING NEUTROPENIA | July 2022 | May 2025 | Allow | 33 | 1 | 0 | No | No |
| 17759538 | METHODS OF TREATING AN INFLAMMATORY OR OBSTRUCTIVE AIRWAY DISEASE USING ANTI-TSLP ANTIBODY | July 2022 | December 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17795814 | COMBINATION THERAPY FOR TREATMENT OF CANCER AND CANCER METASTASIS | July 2022 | December 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17815056 | METHODS FOR TREATMENT OF CANCERS HARBORING AN H3K27M MUTATION | July 2022 | December 2025 | Allow | 40 | 1 | 1 | Yes | No |
| 17815086 | IMMUNOGENIC COMPOSITIONS COMPRISING NUCLEIC ACIDS FOR RAS PEPTIDES AND THEIR USE FOR TREATING CANCER | July 2022 | March 2025 | Allow | 32 | 1 | 0 | No | No |
| 17862952 | SELF-ASSEMBLING SYNTHETIC PROTEINS COMPRISING CHOLERA TOXIN BETA SUBUNIT | July 2022 | June 2025 | Allow | 35 | 1 | 0 | No | No |
| 17830381 | HUMANIZED ANTI-HUMAN-PD-1 ANTIBODY AND METHODS OF USING THEM FOR CANCER TREATMENT | June 2022 | February 2025 | Allow | 33 | 1 | 0 | No | No |
| 17780396 | PHARMACEUTICAL COMPOSITION | May 2022 | November 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17780364 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING AN IMMUNE CHECKPOINT INHIBITOR ANTIBODY AND A FUSION PROTEIN COMPRISING AN IL-2 MUTANT AND A CD80 EXTRACELLULAR DOMAIN | May 2022 | January 2023 | Allow | 7 | 0 | 0 | No | No |
| 17640516 | METHOD FOR ACQUIRING DATA FOR DISTINGUISHING PRESENCE OF CANCER CELLS AND/OR DISTINGUISHING ANTICANCER DRUG RESISTANCE, METHOD FOR ACQUIRING PREDICTION DATA, USE OF DISTINCTION MARKER IN SAME, AND DISTINGUISHING KIT | May 2022 | February 2026 | Abandon | 47 | 1 | 1 | Yes | No |
| 17737159 | RECOMBINANT PROTEIN TARGETING PD-L1 AND VEGF AND COMPOSITIONS THEREOF. | May 2022 | September 2025 | Allow | 41 | 2 | 0 | Yes | No |
| 17736431 | FUSION POLYPEPTIDES COMPRISING INTERLEUKIN 12 AND A METAL-HYDROXIDE BINDING POLYPEPTIDE | May 2022 | September 2025 | Allow | 40 | 0 | 1 | Yes | No |
| 17734694 | Antigenic Peptides For Treatment Of B-Cell Malignancy | May 2022 | May 2023 | Allow | 13 | 1 | 2 | No | No |
| 17730261 | METHODS OF BOOSTING THYMIC REGENERATION IN PATIENTS SUFFERING FROM A THYMIC INJURY BY USING RANKL | April 2022 | May 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17716873 | MASKED INTERLEUKIN-12 POLYPEPTIDES | April 2022 | April 2023 | Allow | 12 | 2 | 0 | Yes | No |
| 17711849 | METHODS AND COMPOSITIONS FOR IDENTIFYING NEOANTIGENS FOR USE IN TREATING CANCER | April 2022 | May 2024 | Allow | 25 | 3 | 1 | No | No |
| 17709706 | NOVEL IL2 AGONISTS AND METHODS OF USE THEREOF | March 2022 | February 2023 | Allow | 11 | 2 | 1 | Yes | No |
| 17699846 | PROPROTEINS AND METHODS OF USE THEREOF | March 2022 | September 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17698657 | BISPECIFIC ANTIBODIES TO ROR1 AND CD3 | March 2022 | May 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17696269 | CROSS-SPECIES ANTI-LATENT TGF-BETA 1 ANTIBODIES AND METHODS OF USE | March 2022 | March 2025 | Allow | 36 | 1 | 0 | No | No |
| 17696222 | MASKED ACTIVATABLE INTERFERON CONSTRUCTS | March 2022 | February 2023 | Allow | 11 | 1 | 2 | Yes | No |
| 17693017 | MESOPOROUS SILICA COMPOSITIONS COMPRISING INFLAMMATORY CYTOKINES FOR MODULATING IMMUNE RESPONSES | March 2022 | April 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17679545 | ANTIBODIES AGAINST IGFR-LIKE RECEPTOR AND USES THEREOF | February 2022 | December 2025 | Allow | 45 | 2 | 0 | No | No |
| 17631161 | METHODS FOR TREATING OR PREVENTING CANCERS INVOLVING THE ADMINISTRATION OF ANTI-CCR5 RECEPTOR AGENTS | January 2022 | March 2026 | Allow | 50 | 1 | 1 | No | No |
| 17571398 | EXTENDED LOCAL RELEASE OF ANTI-CSFR1 ANTIBODIES | January 2022 | May 2022 | Allow | 5 | 1 | 1 | Yes | No |
| 17625076 | ANTIBODIES AGAINST TAU EPITOPES | January 2022 | September 2025 | Allow | 45 | 1 | 1 | No | No |
| 17622467 | HYDROPHILIC LINKERS FOR MULTIVALENT PEPTIDE CONJUGATES | December 2021 | March 2026 | Allow | 51 | 1 | 1 | No | No |
| 17622552 | NOVEL TUMOR-SPECIFIC ANTIGENS FOR OVARIAN CANCER AND USES THEREOF | December 2021 | March 2026 | Allow | 50 | 2 | 1 | No | No |
| 17559301 | NUCLEIC ACIDS ENCODING ANTI-IL1RAP ANTIBODIES AND THEIR USES | December 2021 | March 2025 | Allow | 38 | 1 | 1 | No | No |
| 17554423 | METHOD OF MAKING AFUCOSYLATED ANTI-FGFR2IIIB ANTIBODIES | December 2021 | July 2025 | Allow | 43 | 2 | 0 | No | No |
| 17551679 | IMMUNOGENIC COMPOSITIONS COMPRISING NUCLEIC ACIDS FOR RAS PEPTIDES | December 2021 | April 2022 | Allow | 4 | 1 | 1 | No | No |
| 17551412 | LIGAND-TARGETED CELL CONJUGATE (LTCC)-BASED ANTI-TUMOR IMMUNE CELL | December 2021 | April 2025 | Allow | 40 | 1 | 1 | No | No |
| 17551908 | Methods of treating IL1RAP associated cancers with Anti Human Interleukin-1 Receptor Accessory Protein (IL1 RAP) Antibodies | December 2021 | April 2025 | Allow | 40 | 1 | 1 | No | No |
| 17547034 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | December 2021 | March 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17541765 | STABILIZED PROTEOLYTICALLY ACTIVATED GROWTH DIFFERENTIATION FACTOR 11 | December 2021 | March 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17540477 | COMBINATION IMMUNOTHERAPY FOR TREATMENT OF MELANOMA, COLON OR NON-SMALL CELL LUNG CANCERS | December 2021 | January 2025 | Allow | 38 | 1 | 0 | No | No |
| 17536974 | ANTI-CD40 BINDING MOLECULES HAVING ENGINEERED FC DOMAINS AND THERAPEUTIC USES THEREOF | November 2021 | April 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17533945 | METHODS OF USE FOR ANTI- ILT2 ANTIBODIES | November 2021 | April 2025 | Allow | 40 | 2 | 1 | No | No |
| 17456205 | ANTI-MULLERIAN HORMONE RECEPTOR BINDING PEPTIDES | November 2021 | August 2022 | Allow | 9 | 2 | 0 | No | No |
| 17611046 | METHOD FOR PREPARING IMMUNE-TOLERIZED EXTRACELLULAR VESICLE CONTAINING LACTATE DEHYDROGENASE B AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA, AND COMPOSITION COMPRISING THE EXTRACELLULAR VESICLE | November 2021 | May 2023 | Allow | 18 | 0 | 0 | No | No |
| 17520399 | METHODS AND COMPOSITIONS FOR TREATING ALLERGIC OCULAR DISEASES | November 2021 | March 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17519606 | HIGH CONCENTRATION ANTI-BLYS PHARMACEUTICAL FORMULATIONS | November 2021 | January 2025 | Allow | 38 | 1 | 0 | No | No |
| 17453736 | LYMPHANGIOGENESIS FOR THERAPEUTIC IMMUNOMODULATION | November 2021 | March 2026 | Abandon | 52 | 2 | 1 | No | No |
| 17519082 | Treatment of diuretic resistant heart failure patients having at least one copy of the TMPRSS6 rs855791 allele | November 2021 | July 2025 | Allow | 44 | 2 | 0 | No | No |
| 17506483 | Interleukin-2 variant proteins fused to human IgG4 Fc and uses thereof | October 2021 | September 2023 | Allow | 23 | 1 | 1 | No | No |
| 17451176 | VARIANT SURVIVIN VACCINE FOR TREATMENT OF MYELOMA | October 2021 | February 2025 | Allow | 40 | 1 | 0 | No | No |
| 17500616 | ANTIBODY EPITOPE | October 2021 | August 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17487409 | METHOD FOR INHIBITING PLATELET DERIVED GROWTH FACTOR SIGNALING WITH C3aR OR C5aR ANTIBODIES | September 2021 | May 2025 | Abandon | 44 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner STOICA, ELLY GERALD.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 27.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner STOICA, ELLY GERALD works in Art Unit 1647 and has examined 1,331 patent applications in our dataset. With an allowance rate of 63.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 28 months.
Examiner STOICA, ELLY GERALD's allowance rate of 63.5% places them in the 24% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by STOICA, ELLY GERALD receive 1.71 office actions before reaching final disposition. This places the examiner in the 36% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by STOICA, ELLY GERALD is 28 months. This places the examiner in the 67% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +26.3% benefit to allowance rate for applications examined by STOICA, ELLY GERALD. This interview benefit is in the 73% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 28.5% of applications are subsequently allowed. This success rate is in the 52% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 59.6% of cases where such amendments are filed. This entry rate is in the 85% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 120.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 82% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 86.4% of appeals filed. This is in the 80% percentile among all examiners. Of these withdrawals, 73.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 58.3% are granted (fully or in part). This grant rate is in the 61% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 7.4% of allowed cases (in the 90% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.2% of allowed cases (in the 52% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.